دورية أكاديمية
أعرض في EDS

Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings.

التفاصيل البيبلوغرافية
العنوان: Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings.
المؤلفون: Foeldvari I; Schön Klinik Hamburg Eilbek, Hamburg, Germany., Torok KS; University of Pittsburgh and Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania., Anton J; Hospital Sant Joan de Déu and Universitat de Barcelona, Barcelona, Spain., Blakley M; Indiana University School of Medicine and Riley Hospital for Children at IU Health, Indianapolis., Constantin T; Semmelweis University, Budapest, Hungary., Curran M; University of Colorado School of Medicine and Children's Hospital Colorado, Aurora., Cutolo M; University of Genoa and IRCCS San Martino Polyclinic Hospital, Genoa, Italy., Denton C; Royal Free London NHS Foundation Trust, London, UK., Fligelstone K; Scleroderma & Raynaud's United Kingdom, London, UK., Ingegnoli F; University of Milan, ASST G. Pini, Milan, Italy., Li SC; Hackensack University Medical Center, Hackensack, New Jersey., Němcová D; Charles University, Prague, Czech Republic., Orteu C; Royal Free London, London, UK., Pilkington C; Great Ormond Street Hospital, London, UK., Smith V; Ghent University, Ghent University Hospital, VIB Inflammation Research Center, and ERN ReCONNET, Ghent, Belgium., Stevens A; Children's Hospital Research Institute and University of Washington, Seattle, and Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania., Klotsche J; German Rheumatism Research Center, Berlin, Germany., Khanna D; University of Michigan, Ann Arbor., Costa-Reis P; Hospital de Santa Maria, Faculdade de Medicina, and Universidade de Lisboa, Lisbon, Portugal., Del Galdo F; University of Leeds and Leeds Teaching Hospital Trust, Leeds, UK., Hinrichs B; Asklepios Klinik Nord-Heidberg, Hamburg, Germany., Kasapcopur O; Cerrahpasa Medical School and Istanbul University-Cerrahpasa, Istanbul, Turkey., Pain C; Alder Hey Children's Foundation NHS Trust, Liverpool, UK., Ruperto N; IRCCSG Istituto G. Gaslini, Genoa, Italy., Zheng A; Chinese Organization for Scleroderma, Chengdu City, Sichuan Province, China., Furst DE; University of California, Los Angeles, University of Washington, Seattle, and University of Florence, Florence, Italy.
المصدر: Arthritis care & research [Arthritis Care Res (Hoboken)] 2023 Dec; Vol. 75 (12), pp. 2453-2462. Date of Electronic Publication: 2023 Sep 12.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 101518086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2151-4658 (Electronic) Linking ISSN: 2151464X NLM ISO Abbreviation: Arthritis Care Res (Hoboken) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hoboken, NJ : John Wiley & Sons
مواضيع طبية MeSH: Raynaud Disease*/drug therapy , Scleroderma, Systemic*/diagnosis , Scleroderma, Systemic*/drug therapy , Scleroderma, Systemic*/complications, Adult ; Child ; Humans ; Consensus ; Quality of Life
مستخلص: Objective: Juvenile systemic sclerosis (SSc) is an orphan disease, associated with high morbidity and mortality. New treatment strategies are much needed, but clearly defining appropriate outcomes is necessary if successful therapies are to be developed. Our objective here was to propose such outcomes.
Methods: This proposal is the result of 4 face-to-face consensus meetings with a 27-member multidisciplinary team of pediatric rheumatologists, adult rheumatologists, dermatologists, pediatric cardiologists, pulmonologists, gastroenterologists, a statistician, and patients. Throughout the process, we reviewed the existing adult data in this field, the more limited pediatric literature for juvenile SSc outcomes, and data from 2 juvenile SSc patient cohorts to assist in making informed, data-driven decisions. The use of items for each domain as an outcome measure in an open label 12-month clinical trial of juvenile SSc was voted and agreed upon using a nominal group technique.
Results: After voting, the domains agreed on were global disease activity, skin, Raynaud's phenomenon, digital ulcers, musculoskeletal, cardiac, pulmonary, renal, and gastrointestinal involvement, and quality of life. Fourteen outcome measures had 100% agreement, 1 item had 91% agreement, and 1 item had 86% agreement. The domains of biomarkers and growth/development were moved to the research agenda.
Conclusion: We reached consensus on multiple domains and items that should be assessed in an open label, 12-month clinical juvenile SSc trial as well as a research agenda for future development.
(© 2023 American College of Rheumatology.)
References: Foeldvari I, Klotsche J, Kasapcopur O, et al. Differences sustained between diffuse and limited forms of juvenile systemic sclerosis in an expanded international cohort. Arthritis Care Res (Hoboken) 2022;74:1575-84.
Foeldvari I, Torok KS. Review for best practice in clinical rheumatology juvenile systemic sclerosis: updates and practice points [review]. Best Pract Res Clin Rheumatol 2021;35:101688.
Medsger TA Jr, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
La Torre F, Martini G, Russo R, et al. A preliminary disease severity score for juvenile systemic sclerosis. Arthritis Rheum 2012;64:4143-50.
Khanna D, Berrocal VJ, Giannini EH, et al. The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis Care Res (Hoboken) 2016;68:167-78.
Valentini G, Bencivelli W, Bombardieri S, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62:901-3.
Valentini G, Iudici M, Walker UA, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis 2017;76:270-6.
Klotsche J, Foeldvari I, Kasapcopur O, et al. SAT0500 How the adult CRISS works in pediatric jSSc patients: results from the Juvenile Scleroderma Inception Cohort. Ann Rheum Dis 2020;79:1206.
Stevens BE, Torok KS, Li SC, et al. Clinical characteristics and factors associated with disability and impaired quality of life in children with juvenile systemic sclerosis: results from the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. Arthritis Care Res (Hoboken) 2018;70:1806-13.
Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res (Hoboken) 1992;5:119-29.
Singh G, Athreya BH, Fries JF, et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9.
Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
Johnson SR, Hawker GA, Davis AM. The Health Assessment Questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: an evaluation of their measurement properties. Arthritis Rheum 2005;53:256-62.
Ruperto N, Ravelli A, Pistorio A, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries: review of the general methodology. Clin Exp Rheumatol 2001;19 Suppl 23:S1-9.
Poole JL, Williams CA, Bloch DA, et al. Concurrent validity of the Health Assessment Questionnaire Disability Index in scleroderma. Arthritis Care Res (Hoboken) 1995;8:189-93.
Foeldvari I, Klotsche J, Kasapcopur O, et al. After 24 months observation period the patients related outcomes improve significantly in the Juvenile Scleroderma Inceptions Cohorte [abstract]. Arthritis Rheumatol 2018;70 Suppl 9. URL: https://acrabstracts.org/abstract/after-24-months-observation-period-the-patients-related-outcomes-improve-significantly-in-the-juvenile-scleroderma-inceptions-cohorte/.
Brunner HI, Klein-Gitelman MS, Miller MJ, et al. Minimal clinically important differences of the childhood health assessment questionnaire. J Rheumatol 2005;32:150-61.
Varni JW, Burwinkle TM, Seid M. The PedsQL 4.0 as a school population health measure: feasibility, reliability, and validity. Qual Life Res 2006;15:203-15.
Varni JW, Seid M, Smith Knight T, et al. The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum 2002;46:714-25.
Varni JW, Sherman SA, Burwinkle TM, et al. The PedsQL Family Impact Module: preliminary reliability and validity. Health Qual Life Outcomes 2004;2:55.
Landgraf JM, Maunsell E, Speechley KN, et al. Canadian-French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results. Qual Life Res 1998;7:433-45.
Stevens KJ. Working with children to develop dimensions for a preference-based, generic, pediatric, health-related quality-of-life measure. Qual Health Res 2010;20:340-51.
Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
Scalapino K, Arkachaisri T, Lucas M, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol 2006;33:1004-13.
Pauling JD, Saketkoo LA, Matucci-Cerinic M, et al. The patient experience of Raynaud's phenomenon in systemic sclerosis [review]. Rheumatology (Oxford) 2019;58:18-26.
Frantz C, Avouac J, Distler O, et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey. Semin Arthritis Rheum 2016;46:115-23.
Foeldvari I, Klotsche J, Torok KS, et al. Characteristics of the first 80 patients at timepoint of first assessment included in the Juvenile Systemic Sclerosis Inception Cohort. J Scleroderma Relat Disord 2018;4:1-13.
Gladue H, Maranian P, Paulus HE, et al. Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials. Arthritis Care Res (Hoboken) 2013;65:630-6.
Hughes M, Pauling JD. Exploring the patient experience of digital ulcers in systemic sclerosis [review]. Semin Arthritis Rheum 2019;48:888-94.
Bruni C, Ngcozana T, Braschi F, et al. Preliminary validation of the Digital Ulcer Clinical Assessment Score in systemic sclerosis. J Rheumatol 2019;46:603-8.
Blagojevic J, Bellando-Randone S, Abignano G, et al. Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey. Arthritis Res Ther 2019;21:35.
Low AH, Lax M, Johnson SR, et al. Magnetic resonance imaging of the hand in systemic sclerosis. J Rheumatol 2009;36:961-4.
Martini G, Vittadello F, Kasapcopur O, et al. Factors affecting survival in juvenile systemic sclerosis. Rheumatology (Oxford) 2009;48:119-22.
Bruni C, Buch MH, Furst DE, et al. Primary systemic sclerosis heart involvement: a systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. J Scleroderma Relat Disord 2022;7:24-32.
Foeldvari I, Klotsche J, Hinrichs B, et al. Underdetection of interstitial lung disease in juvenile systemic sclerosis. Arthritis Care Res (Hoboken) 2022;74:364-70.
Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD) [review]. Respir Res 2019;20:13.
Volkmann E. Natural history of systemic sclerosis-related interstitial lung disease: how to identify a progressive fibrosing phenotype. J Scleroderma Relat Disord 2020;5 Suppl:31-40.
Showalter K, Hoffmann A, Rouleau G, et al. Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis. J Rheumatol 2018;45:1572-6.
Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012;40:1324-43.
Beydon N, Davis SD, Lombardi E, et al. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children [review]. Am J Respir Crit Care Med 2007;175:1304-45.
Silver KC, Silver RM. Management of systemic-sclerosis-associated interstitial lung disease [review]. Rheum Dis Clin North Am 2015;41:439-57.
Pugnet G, Marjanovic Z, Deligny C, et al. Reproducibility and utility of the 6-minute walk test in systemic sclerosis. J Rheumatol 2018;45:1273-80.
Vandecasteele E, Melsens K, De Keyser F, et al. A prospective, longitudinal study evaluating the baseline six-minute walk test as an individual reference value in systemic sclerosis patients. Clin Exp Rheumatol 2018;36 Suppl 113:95-101.
Lammers AE, Hislop AA, Flynn Y, et al. The 6-minute walk test: normal values for children of 4-11 years of age. Arch Dis Child 2008;93:464-8.
Miglioretti DL, Johnson E, Williams A, et al. The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr 2013;167:700-7.
Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017;140:e20171904.
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120:c179-84.
Martini G, Foeldvari I, Russo R, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum 2006;54:3971-8.
Gyger G, Baron M. Systemic sclerosis: gastrointestinal disease and its management [review]. Rheum Dis Clin North Am 2015;41:459-73.
Tu J, Cheung WW, Mak RH. Inflammation and nutrition in children with chronic kidney disease [review]. World J Nephrol 2016;5:274-82.
Duggan C, Watkins J, Walker A, et al. Clinical assessment of nutritional status. In: Nutrition in pediatrics: basic science, clinical applications. BC Decker; 2008. p. 5-13.
Lovell DJ, Ruperto N, Giannini EH, et al. Advances from clinical trials in juvenile idiopathic arthritis [review]. Nat Rev Rheumatol 2013;9:557-63.
SCR Disease Name: digital ulcers; Juvenile systemic scleroderma; Juvenile-onset scleroderma
تواريخ الأحداث: Date Created: 20230618 Date Completed: 20231130 Latest Revision: 20231221
رمز التحديث: 20231221
DOI: 10.1002/acr.25171
PMID: 37332054
قاعدة البيانات: MEDLINE
الوصف
تدمد:2151-4658
DOI:10.1002/acr.25171